<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613313</url>
  </required_header>
  <id_info>
    <org_study_id>Lipoma DE/01</org_study_id>
    <nct_id>NCT01613313</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma</brief_title>
  <official_title>A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zachary Gerut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advance Biofactures Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gerut, Zachary, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the safest and most effective dose of a Food and
      Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors of
      varying sizes that occur commonly in the adult population). The fat in the lipoma is like
      normal fat except that it is enclosed in a balloon-like structure which is made of collagen
      (fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks
      down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size
      of the lipoma or removing it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipomas are common mesenchymal, benign, fatty tumors of varying sizes that occur in the
      general adult population. They usually present as painful or annoying lumps that are palpable
      and often visible in the subcutaneous tissue. Many subcutaneous lipomas are asymptomatic and
      are removed for non-medical reasons. However, they may cause the subject pain or discomfort
      or interfere with normal activity.

      Spontaneous remission of lipomas has not been reported. A lipoma, once it presents itself,
      remains there for the lifetime of a person who carries it and may stay small or become
      larger. Alternative treatments of the lipoma are surgery or liposuction. If a large excision
      is performed there is the problem of having a very large scar and the accompanying issues of
      healing a large scar, or possible formation of a hematoma followed by consolidation of the
      hematoma and the remnants of a mass of scar tissue. This is often painful and more
      problematic than the original lipoma. liposuction also has the potential for hematoma
      formation followed by scar mass residual.

      To avoid the complications listed above, a non-invasive method of treatment, such as enzyme
      mediated disassociation of adipose tissue, would be desirable. The primary aim of this study
      is to perform a step-wise approach in dosing to evaluate the safety and efficacy of
      clostridium histolyticum as a non-operative treatment for lipoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visible Surface Area of the Lipoma</measure>
    <time_frame>Baseline and Six months post injection of study drug</time_frame>
    <description>The primary efficacy outcome is the visible surface area of the lipoma measured as the longest dimension (length) times the longest dimension perpendicular to length (width). Visible surface area will be determined by caliper and will be analyzed as the percent change from baseline at the 6-month post injection visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Volume of the Lipoma</measure>
    <time_frame>Baseline and 6 months post injection of study drug</time_frame>
    <description>A secondary outcome is the relative change in volume of the lipoma as determined by MRI. This outcome will be analyzed as the change from baseline to 6 months post injection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Lipoma</condition>
  <arm_group>
    <arm_group_label>Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection 0.058 mg Collagenase Clostridium Histolyticum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection 0.15 mg Collagenase Clostridium Histolyticum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection 0.29 mg Collagenase Clostridium Histolyticum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose #4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection 0.44 mg Collagenase Clostridium Histolyticum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Collagenase Clostridium Histolyticum</intervention_name>
    <description>This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
    <arm_group_label>Dose #1</arm_group_label>
    <arm_group_label>Dose #2</arm_group_label>
    <arm_group_label>Dose #3</arm_group_label>
    <arm_group_label>Dose #4</arm_group_label>
    <other_name>XIAFLEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical history lipoma at least one year and no treatment within last 90 days

          -  Lipoma diagnosed as benign

          -  Lipoma is a single mass with easily definable edges

          -  Lipoma has an area of 2.0 to 17 cm squared

          -  Women of childbearing potential must use an acceptable method of birth control

        Exclusion Criteria:

          -  Lipomas on the head, neck, hand or foot, or female breast

          -  Women who are nursing or pregnant

          -  Subjects who have participated in any investigational drug trial within 45 days of
             enrollment in this study

          -  Subjects with known allergy to collagenase or any of the inactive ingredients in
             XIAFLEX

          -  Subjects with diabetes or any medical condition that would make the subject unsuitable
             for enrollment.

          -  Subjects having a history of trauma in the area of the lipoma

          -  Subjects with a history of connective tissue diseases or rheumatological diseases.

          -  Subjects with uncontrolled hypertension

          -  Subjects currently receiving or planning to receive anticoagulant medication except
             for less than 150 mg aspirin daily and over-the-counter nonsteroidal anti-inflammatory
             drugs) within 7 days before injection of study drug

          -  Subjects having the following laboratory abnormalities:

          -  ALT/AST greater than 3 times the upper limit of normal

          -  Creatinine greater than 2

          -  Hemoglobin/hematocrit and WBC outside the normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary E Gerut, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerut, Zachary, M.D.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zachary E. Gerut, M.D.</name>
      <address>
        <city>Hewlett</city>
        <state>New York</state>
        <zip>11557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <results_first_submitted>February 10, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2016</results_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Gerut, Zachary, M.D.</investigator_affiliation>
    <investigator_full_name>Zachary Gerut</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Lipoma</keyword>
  <keyword>Fatty Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 1 site in the United States</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose #1</title>
          <description>single injection 0.058 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="P2">
          <title>Dose #2</title>
          <description>single injection 0.15 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="P3">
          <title>Dose #3</title>
          <description>single injection 0.29 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="P4">
          <title>Dose #4</title>
          <description>single injection 0.44 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose #1</title>
          <description>single injection 0.058 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="B2">
          <title>Dose #2</title>
          <description>single injection 0.15 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="B3">
          <title>Dose #3</title>
          <description>single injection 0.29 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="B4">
          <title>Dose #4</title>
          <description>single injection 0.44 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="5.66"/>
                    <measurement group_id="B2" value="51.5" spread="12.50"/>
                    <measurement group_id="B3" value="41.3" spread="11.09"/>
                    <measurement group_id="B4" value="57.0" spread="4.97"/>
                    <measurement group_id="B5" value="49.6" spread="10.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visible Surface Area of the Lipoma</title>
        <description>The primary efficacy outcome is the visible surface area of the lipoma measured as the longest dimension (length) times the longest dimension perpendicular to length (width). Visible surface area will be determined by caliper and will be analyzed as the percent change from baseline at the 6-month post injection visit.</description>
        <time_frame>Baseline and Six months post injection of study drug</time_frame>
        <population>Analysis population consists of all subjects who were enrolled and received the administration of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose #1</title>
            <description>single injection 0.058 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
          <group group_id="O2">
            <title>Dose #2</title>
            <description>single injection 0.15 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
          <group group_id="O3">
            <title>Dose #3</title>
            <description>single injection 0.29 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
          <group group_id="O4">
            <title>Dose #4</title>
            <description>single injection 0.44 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visible Surface Area of the Lipoma</title>
          <description>The primary efficacy outcome is the visible surface area of the lipoma measured as the longest dimension (length) times the longest dimension perpendicular to length (width). Visible surface area will be determined by caliper and will be analyzed as the percent change from baseline at the 6-month post injection visit.</description>
          <population>Analysis population consists of all subjects who were enrolled and received the administration of study drug.</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.69" spread="80.83"/>
                    <measurement group_id="O2" value="-47.57" spread="23.48"/>
                    <measurement group_id="O3" value="-52.42" spread="50.61"/>
                    <measurement group_id="O4" value="-66.60" spread="17.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is a proof of concept dose escalation study. No power justification has been implemented. Descriptive data provided for each arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>50</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in Volume of the Lipoma</title>
        <description>A secondary outcome is the relative change in volume of the lipoma as determined by MRI. This outcome will be analyzed as the change from baseline to 6 months post injection.</description>
        <time_frame>Baseline and 6 months post injection of study drug</time_frame>
        <population>Analysis is based on the population that consists of all subjects who are enrolled and received administration of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Dose #1</title>
            <description>single injection 0.058 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
          <group group_id="O2">
            <title>Dose #2</title>
            <description>single injection 0.15 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
          <group group_id="O3">
            <title>Dose #3</title>
            <description>single injection 0.29 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
          <group group_id="O4">
            <title>Dose #4</title>
            <description>single injection 0.44 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Volume of the Lipoma</title>
          <description>A secondary outcome is the relative change in volume of the lipoma as determined by MRI. This outcome will be analyzed as the change from baseline to 6 months post injection.</description>
          <population>Analysis is based on the population that consists of all subjects who are enrolled and received administration of study drug</population>
          <units>Percent reduction from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.16" spread="34.3"/>
                    <measurement group_id="O2" value="-62.33" spread="30.39"/>
                    <measurement group_id="O3" value="-11.35" spread="32.12"/>
                    <measurement group_id="O4" value="-34.75" spread="24.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is a proof of concept dose escalation study. No power of justification was implemented. Descriptive statistics was provided for each arm only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>50</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from Day 0 through 6 months post administration of study medication</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose #1</title>
          <description>single injection 0.058 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="E2">
          <title>Dose #2</title>
          <description>single injection 0.15 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="E3">
          <title>Dose #3</title>
          <description>single injection 0.29 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
        <group group_id="E4">
          <title>Dose #4</title>
          <description>single injection 0.44 mg Collagenase Clostridium Histolyticum
Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>Injection site reaction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Injection Site</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Injection site</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zachary E.Gerut</name_or_title>
      <organization>GerutZ</organization>
      <phone>516 295-2100</phone>
      <email>Drgerut@drgerut.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

